Abbott said that an ongoing multisite clinical study indicated that its rapid COVID-19 test was accurate when detecting the virus nearly 95% of the time. Abbott said that an ongoing multisite ...

Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year ...

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

The test in question developed by Abbott and SD Biosensor costs around ... months to distribute in countries badly affected by the coronavirus. In an email conversation with pharmaphorum a ...

Some test kits with expiration dates printed ... For example, a pack of two BinaxNow COVID-19 antigen self-tests from Abbott costs $18.99 at CVS.com. Other government efforts aimed at stemming ...

For full-year 2025, the company forecast organic sales growth between 7.5% and 8.5% as well as adjusted earnings per share in the range of $5.05 and $5.25. Analysts polled by FactSet expect $42 ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott’s device business has been a bright spot as litigation over its baby formula products and declining demand for its COVID tests have dragged on shares. The organization that filed the ...

The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.